Aspen Pharmacare Canada announced that Health Canada has approved ᴾʳAspen-Semaglutide, a generic equivalent of Ozempic® (semaglutide injection), for the treatment of adults with type 2 diabetes mellitus to improve glycemic control, in combination with diet and exercise. Aspen-Semaglutide will offer both the 2 mg and 4 mg pen formats.
Aspen-Semaglutide is approved in 2 mg and 4 mg pre-filled pen formats, delivering:
- 0.25 mg or 0.5 mg doses (2 mg / pen; 1.34 mg/mL)
- 1 mg doses (4 mg / pen; 1.34 mg/mL)
"Semaglutide is an important treatment option for many adults living with type 2 diabetes. We recognize the need for alternatives in this category and look forward to working with Canadian stakeholders to support availability following launch", said Mike Egli, General Manager of Aspen Pharmacare Canada.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!